Prazosin

• Description:

  Prazosin is an α-adrenergic receptor antagonist. Prazosin can reduce inflammation, relieve anxiety, alleviate panic, prevent memory decline, and modulate the pain-relieving effects of opioids. Prazosin can be used in the study of hypertension and Alzheimer’s disease[1][2][3][4].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Adrenergic Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Cardiovascular Disease; Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/Prazosin.html

• Concentration:

  10mM

• Purity:

  99.80

• Solubility:

  DMSO : 41.67 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C(N1CCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)CC1)C4=CC=CO4

• Molecular Formula:

  C19H21N5O4

• Molecular Weight:

  383.40

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Day HE, et al. Distribution of alpha 1a-, alpha 1b- and alpha 1d-adrenergic receptor mRNA in the rat brain and spinal cord. J Chem Neuroanat. 1997 Jul;13 (2) :115-39.|[2]Elizabeth K Lucas, et al. Prazosin during fear conditioning facilitates subsequent extinction in male C57Bl/6N mice. Psychopharmacology (Berl) . 2019 Jan;236 (1) :273-279.|[3]Loukia Katsouri, et al. Prazosin, an α (1) -adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer's disease. Neurobiol Aging. 2013 Apr;34 (4) :1105-15. |[4]Umit Kazim Ozdoğan, et al. Influence of prazosin and clonidine on morphine analgesia, tolerance and withdrawal in mice. Eur J Pharmacol. 2003 Jan 24;460 (2-3) :127-34.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, stored under nitrogen)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  Am J Pathol. 2023 Jul;193 (7) :913-926.|Biomed Pharmacother. 2020 Apr;124:109731.|Cells. 2023 May 24;12 (11) :1461.|Drug Des Devel Ther. 2024 Apr 9:18:1103-1114.|Elife. 2024 May 29.|J Med Chem. 2021 Mar 11;64 (5) :2725-2738.|Redox Rep. 2025 Dec;30 (1) :2494314.|bioRxiv. 2024 November 03.|BMC Pulm Med. 2021 Jun 5;21 (1) :189.|Cell Discov. 2023 Feb 7;9 (1) :16.|Cell Rep Med. 2024 Oct 1:101771.|iScience. 2025 Jan 17;28 (2) :111831.|J Exp Med. 2023 Nov 6;220 (11) :e20230577.|J Transl Med. 2022 Oct 2;20 (1) :444.|Nature. 2025 Dec;648 (8092) :146-156.

• CAS Number:

  [19216-56-9]